2024 Volume 24 Issue 1 Pages 96-101
The number of patients who requires genetic test for BRCA1/2 are increasing after the indication was expanded to include companion diagnosis for olaparib. The backgrounds and purposes of patients seeking analyses are diverse. There is also an increasing demand for genetic test from unaffected family members of patients with BRCA1/2 pathogenic variants. Single-site analyses for BRCA1/2 genetic test was performed on three unaffected adults and one postoperative breast cancer patient at our institution. As single-site analyses are not being covered by public health insurance system, it was noted that additional testing of BRACAnalysisⓇ would be required for a companion diagnosis in cases considering the eligibility for Olaparib. Comprehensive screening system in several cancer surveillance has not been established enough for unaffected carriers with BRCA1/2 pathogenic variants. The demand for single-site analyses of unaffected family members with BRCA1/2 pathogenic variants is expected to increase in the future. It is anticipated that expansion of support systems to support unaffected carriers, including an appropriate medical care.
